Safety-Related Labeling Changes
Pulmonary embolism, Posterior reversible encephalopathy syndrome, Skin hyperpigmentation (serpentine supravenous hyperpigmentation)
Trade Name
Navelbine
Updated Section
4.8 Undesirable effects
Month
Jan,2023